Cystadenoma serous. Medical search

A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)

A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.

A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)

A benign neoplasm of the ovary.

A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)

Tumors or cancer of the APPENDIX.

A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)

Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.

Tumors or cancer of the BILE DUCTS.

A worm-like blind tube extension from the CECUM.

A benign tumor of the intrahepatic bile ducts.

Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.

A sex cord-gonadal stromal tumor consists of LEYDIG CELLS; SERTOLI CELLS; and FIBROBLASTS in varying proportions and degree of differentiation. Most such tumors produce ANDROGENS in the Leydig cells, formerly known as androblastoma or arrhenoblastoma. Androblastomas occur in the TESTIS or the OVARY causing precocious masculinization in the males, and defeminization, or virilization (VIRILISM) in the females. In some cases, the Sertoli cells produce ESTROGENS.

Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.

Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).

A benign tumor characterized histologically by tall columnar epithelium within a lymphoid tissue stroma. It is usually found in the salivary glands, especially the parotid.

A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)

Pathological developments in the CECUM.

Predominantly extrahepatic bile duct which is formed by the junction of the right and left hepatic ducts, which are predominantly intrahepatic, and, in turn, joins the cystic duct to form the common bile duct.

A cystic dilation of the EPIDIDYMIS, usually in the head portion (caput epididymis). The cyst fluid contains dead SPERMATOZOA and can be easily differentiated from TESTICULAR HYDROCELE and other testicular lesions.

Tumors or cancer of the ENDOCRINE GLANDS.

Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

A condition characterized by the complete absence of SEMEN. This disorder should be differentiated from AZOOSPERMIA, absence of sperm in the semen.

A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)

Tumors or cancer of the SALIVARY GLANDS.

A true cyst of the PANCREAS, distinguished from the much more common PANCREATIC PSEUDOCYST by possessing a lining of mucous EPITHELIUM. Pancreatic cysts are categorized as congenital, retention, neoplastic, parasitic, enterogenous, or dermoid. Congenital cysts occur more frequently as solitary cysts but may be multiple. Retention cysts are gross enlargements of PANCREATIC DUCTS secondary to ductal obstruction. (From Bockus Gastroenterology, 4th ed, p4145)

Surgery performed on the male genitalia.

Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.

Accessory salivary glands located in the lip, cheek, tongue, floor of mouth, palate and intramaxillary.

Tomography using x-ray transmission and a computer algorithm to reconstruct the image.

Cyst-like space not lined by EPITHELIUM and contained within the PANCREAS. Pancreatic pseudocysts account for most of the cystic collections in the pancreas and are often associated with chronic PANCREATITIS.

General term for CYSTS and cystic diseases of the OVARY.

Non-invasive diagnostic technique for visualizing the PANCREATIC DUCTS and BILE DUCTS without the use of injected CONTRAST MEDIA or x-ray. MRI scans provide excellent sensitivity for duct dilatation, biliary stricture, and intraductal abnormalities.

Pathological processes of the PANCREAS.

Passages external to the liver for the conveyance of bile. These include the COMMON BILE DUCT and the common hepatic duct (HEPATIC DUCT, COMMON).

Surgical removal of the vermiform appendix. (Dorland, 28th ed)

Surgical removal of the pancreas. (Dorland, 28th ed)

A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)

An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)

Neoplasms containing cyst-like formations or producing mucin or serum.

It is a form of protection provided by law. In the United States this protection is granted to authors of original works of authorship, including literary, dramatic, musical, artistic, and certain other intellectual works. This protection is available to both published and unpublished works. (from Circular of the United States Copyright Office, 6/30/2008)

A subspecialty of pathology applied to the solution of clinical problems, especially the use of laboratory methods in clinical diagnosis. (Dorland, 28th ed.)

Inflammation of the OVARY, generally caused by an ascending infection of organisms from the endocervix.

A chronic inflammatory condition of the KIDNEY resulting in diffuse renal destruction, a grossly enlarged and nonfunctioning kidney associated with NEPHROLITHIASIS and KIDNEY STONES.

A condition marked by the development of widespread xanthomas, yellow tumor-like structures filled with lipid deposits. Xanthomas can be found in a variety of tissues including the SKIN; TENDONS; joints of KNEES and ELBOWS. Xanthomatosis is associated with disturbance of LIPID METABOLISM and formation of FOAM CELLS.

A cyst (CYSTS) near the OVARY, derived from anomalies of the FALLOPIAN TUBES or the BROAD LIGAMENT. The paramesonephric type consists of ciliated cells similar to the oviduct epithelium. The mesonephric type consisted of an epithelium with minimally surface structures. They can be found on the thin oviduct (paratubal cysts) or near its fimbriated end (hydatid of Morgagni).

A method of providing future reproductive opportunities before a medical treatment with known risk of loss of fertility. Typically reproductive organs or tissues (e.g., sperm, egg, embryos and ovarian or testicular tissues) are cryopreserved for future use before the medical treatment (e.g., chemotherapy, radiation) begins.

Diseases of the uterine appendages (ADNEXA UTERI) including diseases involving the OVARY, the FALLOPIAN TUBES, and ligaments of the uterus (BROAD LIGAMENT; ROUND LIGAMENT).

"The business or profession of the commercial production and issuance of literature" (Webster's 3d). It includes the publisher, publication processes, editing and editors. Production may be by conventional printing methods or by electronic publishing.

The aggregate enterprise of manufacturing and technically producing books. (From Random House Unabridged Dictionary, 2d ed)

The study of animals - their morphology, growth, distribution, classification, and behavior.

A publication issued at stated, more or less regular, intervals.

A quantitative measure of the frequency on average with which articles in a journal have been cited in a given period of time.

Copies of a work or document distributed to the public by sale, rental, lease, or lending. (From ALA Glossary of Library and Information Science, 1983, p181)

The study, control, and application of the conduction of ELECTRICITY through gases or vacuum, or through semiconducting or conducting materials. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)

Overexpression of H-Ryk in mouse fibroblasts confers transforming ability in vitro and in vivo: correlation with up-regulation in epithelial ovarian cancer. (1/109)

Abnormalities in the function of receptor tyrosine kinases (RTKs) have been demonstrated to be important in the pathogenesis of cancer. H-Ryk, a new member of the RTK family, is an unusual RTK in that it is catalytically inactive because of amino acid substitutions of conserved residues in the catalytic domain. We show by immunohistochemistry that it is expressed in the epithelium, stroma, and blood vessels of normal tissues. Evaluation of a panel of 33 primary ovarian tumors (2 benign, 8 borderline, and 23 malignant) was performed. H-Ryk was overexpressed in borderline and malignant ovarian tumors. In serous and clear cell subtypes, there was increased expression in the epithelium, stroma, and blood vessels. Consistent with this observation, overexpression of H-Ryk in the mouse fibroblast cell line NIH3T3 induces anchorage-independent growth and tumorigenicity in nude mice. This implies that overexpression of the receptor can be transforming and may therefore be significant in the pathogenesis of ovarian cancer. (+info)

Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. (2/109)

AIM: To determine whether three-dimensional power Doppler can improve the recognition of pelvic tumor morphology and angiogenesis. METHODS: Using this technique we analyzed 180 adnexal masses and 110 uterine lesions. Tumor volume, morphology, and vascularity were evaluated in each patient. Irregular and randomly dispersed vessels with complex branching depicted by comprehensive three dimensional display were suggestive of pelvic malignancy, while linear-like vascular morphology, single vessel arrangement and regular branching were typical for benign structures. RESULTS: Addition of qualitative analysis of vascular architecture of adnexal tumor to morphological parameters reached 96.15% sensitivity and 98.73% specificity. When endometrial lesions were prospectively analyzed, sensitivity and specificity were 91.67% and 98.49%, respectively. Because the lowest positive predictive value of 16.67% was obtained for myometrial lesions, this method should not be advised for their eva luation. CONCLUSION: Good results achieved by three dimensional ultrasound can be explained by improved recognition of the pelvic lesion anatomy, characterization of the surface features, detection of the tumor infiltration, and precise depiction of the size and volume. Three dimensional power Doppler imaging can detect structural abnormalities of the malignant tumor vessels, such as arteriovenous shunts, microaneurysms, tumoral lakes, disproportional calibration, coiling, and dichotomous branching. Therefore it enhances and facilitates the morphologic and functional evaluation of both benign and malignant pelvic tumors. (+info)

Clinical significance of magnetic resonance cholangiopancreatography for the diagnosis of cystic tumor of the pancreas compared with endoscopic retrograde cholangiopancreatography and computed tomography. (3/109)

BACKGROUND: Cystic tumor of the pancreas has been investigated by a variety of imaging techniques. Magnetic resonance cholangiopancreatography (MRCP) is being widely used as a non-invasive diagnostic modality for investigation of the biliary tree and pancreatic duct system. The purpose of this study was to compare MRCP images with those of endoscopic retrograde cholangiopancreatography (ERCP) and computed tomography (CT) in order to clarify the diagnostic efficacy of MRCP for cystic tumor of the pancreas. METHODS: We retrospectively studied 15 patients with cystic tumor of the pancreas that had been surgically resected and histopathologically confirmed. There were five cases of intraductal papillary adenocarcinoma, five of intraductal papillary adenoma, two of serous cyst adenoma, two of retention cyst associated with invasive ductal adenocarcinoma and one of solid cystic tumor. RESULTS: In all cases MRCP correctly identified the main pancreatic duct (MPD) and showed the entire cystic tumor and the communication between the tumor and the MPD. On the other hand, the detection rate by ERCP of the cystic tumor and the communication between the cystic tumor and the MPD was only 60%. Although the detection rates by CT for the septum and solid components inside the cystic tumor were 100 and 90.0%, respectively, those of MRCP for each were 58.3 and 20.0%. CONCLUSION: MRCP is capable of providing diagnostic information superior to ERCP for the diagnosis of cystic tumor of the pancreas. Although MRCP may provide complementary information about the whole lesion of interest, the characteristic internal features of cystic tumor of the pancrease should be carefully diagnosed in combination with CT. (+info)

Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. (4/109)

OBJECTIVE: To review the features of patients with benign and malignant cystadenomas of the pancreas, focusing on preoperative diagnostic accuracy and long-term outcome, especially for nonoperated serous cystadenomas and resected cystadenocarcinomas. SUMMARY BACKGROUND DATA: Serous cystadenomas (SCAs) are benign tumors. Mucinous cystic neoplasms should be resected because of the risk of malignant progression. A correct preoperative diagnosis of tumor type is based on morphologic criteria. Despite the high quality of recent imaging procedures, the diagnosis frequently remains uncertain. Invasive investigations such as endosonography and diagnostic aspiration of cystic fluid may be helpful, but their assessment is limited to small series. The management of typical SCA may require resection or observation. Survival after pancreatic resection seems better for cystadenocarcinomas (MCACs) than for ductal adenocarcinomas of the pancreas. METHODS: Three hundred ninety-eight cases of cystadenomas of the pancreas were collected between 1984 and 1996 in 73 institutions of the French Surgical Association. Clinical presentation, radiologic evaluation, and surgical procedures were analyzed for 144 operated SCAs, 150 mucinous cystadenomas (MCAs), and 78 MCACs. The outcome of 372 operated patients and 26 nonoperated patients with SCA was analyzed. RESULTS: Cystadenomas represented 76% of all primary pancreatic cystic tumors (398/522). An asymptomatic tumor was discovered in 32% of patients with SCA, 26% of those with MCA, and 13% of those with MCAC. The tumor was located in the head or uncinate process of the pancreas in 38% of those with SCA, 27% of those with MCA, and 49% of those with MCAC. A communication between the cyst and pancreatic duct was discovered in 0.6% of those with SCA, 6% of those with MCA, and 10% of those with MCAC. The main investigations were ultrasonography and computed tomography (94% for SCA, MCA, and MCAC), endosonography (34%, 28%, and 22% for SCA, MCA, and MCAC respectively), endoscopic retrograde cholangiopancreatography (16%, 14%, 22%), and cyst fluid analysis (22%, 31%, 35%). An accurate preoperative diagnosis of tumor type was proposed for 20% of those with SCA (144 cases), 30% of those with MCA, and 29% of those with MCAC. An atypical unilocular macrocyst was observed in 10% of SCA cases. The most common misdiagnosis for mucinous cystic tumors was pseudocyst (9% of MCAs, 15% of MCACs). Intraoperative frozen sections (126 cases) allowed a diagnosis according to definitive histologic examination in 50% of those with SCA and MCA and 62% of those with MCAC. For management, 93% of patients underwent surgery. Nonoperated patients (7%) had exclusively typical SCA. A complete cyst excision was performed in 94% of benign cystadenomas, with an operative mortality rate of 2% for SCA and 1.4% for MCA. Resection was possible in 74% of cases of MCAC. Mean follow-up of 26 patients with nonresected SCAs was 38 months, and no patients required surgery. For resected MCACs, the actuarial 5-year survival rate was 63%. CONCLUSIONS: Spiral computed tomography is the examination of choice for a correct prediction of tumor type. Endosonography may be useful to detect the morphologic criteria of small tumors. Diagnostic aspiration of the cyst allows differentiation of the macrocystic form of SCA (10% of cases) and the unilocular type of mucinous cystic neoplasm from a pseudocyst. Surgical resection should be performed for symptomatic SCAs, all mucinous cystic neoplasms, and cystic tumors that are not clearly defined. Conservative management is wholly justified for a well-documented SCA with no symptoms. An extensive resection is warranted for MCAC because the 5-year survival rate may exceed 60%. (+info)

Three-dimensional power Doppler sonography: imaging and quantifying blood flow and vascularization. (5/109)

OBJECTIVES: To assess the feasibility of imaging low-velocity blood flow in adnexal masses by transvaginal three-dimensional power Doppler sonography, to analyze three-dimensional power Doppler sonography data sets with a new computer-assisted method and to test the reproducibility of the technique. METHODS: A commercially available 5-MHz Combison 530 ultrasound system was used to perform three-dimensional power Doppler sonography transvaginally. A cube (= volume of interest) was defined enclosing the vessels of the cyst and the Cartesian characteristics were stored on a hard disk. This cube was analyzed using specially designed software. Five indices representing vascularization (the vascularization index (VI) or blood flow (the flow index (FI)) or both (the vascularization-flow index (VFI)) were calculated. The intraobserver repeatability of cube definition and scan repetition was assessed using Hartley's test for homogeneous variances. Interobserver agreement was assessed by the Pearson correlation coefficient. RESULTS: Imaging of vessels with low-velocity blood flow by three-dimensional power Doppler sonography and cube definition was possible in all adnexal massed studied. In some cases even induced non-vascular flow related to endometriosis was detected. The calculated F value with intraobserver repeated Cartesian file-saving ranged from 0 to 18.8, with intraobserver scan repetition from 4.74 to 24.8 for VI, FI 1, FI 2 and VFI 1; for VFI 2 the calculated F value was 64. The interobserver correlation coefficient ranged between 0.83 and 0.92 for VI, FI 1, FI 2 and VFI 1; for VFI 2 the correlation coefficient was less than 0.75. CONCLUSION: Vessels with low-velocity blood flow can be imaged using three-dimensional power Doppler sonography. Induced non-vascular flow was detected in endometriotic cyst fluid. Three-dimensional power Doppler sonography combined with the cube method gave reproducible information for all indices except VFI 2. These indices might prove to be a new predictor in all fields of neoangiogenesis. The clinical relevance remains to be determined. (+info)

Cystic struma ovarii: a rare presentation of an infrequent tumor. (6/109)

CONTEXT: Struma ovarii, a rare neoplasm, is a monophyletic teratoma composed of thyroid tissue. It is generally considered to account for less than 5% of mature teratomas. CASE REPORT: A diagnosis of struma ovarii may be the source of many diagnostic problems. It may be cystic and microscopic examination may only reveal a few typical thyroid follicles, resulting in confusion with other cystic ovarian tumors. Extensive sampling should be undertaken and immunohistochemistry may be decisive in establishing the thyroid nature of the epithelial lining. The authors report two cases of cystic struma ovarii, and discuss diagnostic criteria and the limitations of frozen biopsies in these tumors. (+info)

Expression of a homeobox gene (SIX5) in borderline ovarian tumours. (7/109)

AIMS: To assess the expression of SIX5 (a homeobox gene) mRNA in surface coelomic epithelium, endocervical epithelium, Fallopian tube epithelium, and benign, borderline, and malignant epithelial ovarian tumours. METHODS: 10 normal premenopausal ovaries, 10 normal Fallopian tubes, 10 normal cervices, 10 normal postmenopausal ovaries, 10 benign epithelial ovarian tumours, 10 malignant epithelial ovarian tumours, and 40 borderline epithelial ovarian tumours were studied retrospectively. The tissues had been fixed in formalin and embedded in paraffin wax. The tumours had previously been typed into mucinous, serous, or mixed tumours and assigned to the borderline category according to the FIGO/WHO criteria. Expression was assessed by in situ binding of SIX5 specific sense and antisense riboprobes. Hybridization of the riboprobes was detected using a standard immunohistochemical technique and the results correlated with expression in the normal epithelium of the endocervix, Fallopian tube, surface coelomic epithelium, and ovarian tumours. RESULTS: Expression of SIX5 mRNA was demonstrated in normal Fallopian tube epithelium and normal endocervical epithelium. SIX5 mRNA was not detected in normal ovarian epithelial tissue at any of the times studied during the menstrual cycle. Expression of SIX5 was not shown in benign epithelial ovarian tumours or in any of the malignant epithelial ovarian tumours. In 31 of 37 borderline epithelial ovarian tumours (84%), SIX5 expression was found in the epithelial cells. CONCLUSIONS: SIX5 expression is present in the normal epithelium throughout most of the female reproductive tract, suggesting it may have a role in maintaining epithelial differentiation in these tissues. SIX5 expression appears to be restricted to borderline epithelial ovarian tumours and may be a marker of epithelial differentiation in these tumours; thus borderline ovarian tumours may not be part of a continuum of disease between benign and malignant epithelial ovarian tumours. Further investigation of expression of SIX5 may clarify the molecular processes that promote differentiation of the ovarian surface epithelium. (+info)

Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. (8/109)

The high mobility group I (HMGI) family of proteins in mammals belongs to a group of nonhistone nuclear proteins known as architectural transcriptional factors. They function in vivo as both structural components of chromatin and auxiliary gene transcription factors. In an earlier study (N. Abe et al, Cancer Res., 59: 1169-1174, 1999), we demonstrated that the expression level of the HMGI(Y) gene/proteins was significantly increased in colorectal adenocarcinoma and colorectal adenoma with severe cellular atypia. In the current study, we analyzed HMGI(Y) expression in several human pancreatic lesions to investigate (a) whether HMGI(Y) overexpression is also observed in pancreatic carcinoma, and (b) the role of HMGI(Y) in the diagnosis of pancreatic neoplasms. To this end, HMGI(Y) expression was determined at the protein level by immunohistochemistry using a HMGI(Y)-specific antibody in 6 surgically resected specimens of nonneoplastic tissue (4 specimens of normal pancreatic tissue and 2 specimens of chronic pancreatitis tissue), 8 pancreatic cystic neoplasms (5 intraductal papillary mucinous adenomas, 1 serous cystadenoma, and 2 solid pseudopapillary tumors), and 15 duct cell carcinomas of the pancreas. Immunohistochemical analysis revealed intense nuclear staining in the pancreatic carcinoma cells, whereas only very faint nuclear staining was seen in the nonneoplastic cells. There was a strong correlation between HMGI(Y) protein overexpression and a diagnosis of carcinoma (P = 0.000018). Thus, an increased expression level of the HMGI(Y) proteins was clearly associated with the malignant phenotype in pancreatic tissue. In addition, a low level of protein expression was also apparent in two of the cystic neoplasms that exhibited cellular atypia, but not in those that did not exhibit cellular atypia. Based on these findings, we propose that the HMGI(Y) proteins could be closely associated with tumorigenesis in the pancreas and that HMGI(Y) could serve as a potential diagnostic molecular marker for distinguishing pancreatic malignancies unambiguously from normal tissue or benign lesions. (+info)

Tseng JF (March 2008). "Management of serous cystadenoma of the pancreas". J. Gastrointest. Surg. 12 (3): 408-10. doi:10.1007/ ...

https://en.wikipedia.org/wiki/Surgical_Outcomes_Analysis_and_Research

Pancreatic mucinous cystic neoplasm Pancreatic serous cystadenoma Solid pseudopapillary neoplasm "Intraductal Papillary ... Next, the investigators tested harmless cysts such as serous cystadenomas, and the harmless cysts did not have GNAS or KRAS ...

https://en.wikipedia.org/wiki/Intraductal_papillary_mucinous_neoplasm

Solid pseudopapillary neoplasm Pancreatic serous cystadenoma Intraductal papillary mucinous neoplasm Theruvath TP, Morgan KA, ...

https://en.wikipedia.org/wiki/Pancreatic_mucinous_cystic_neoplasm

revdel) Pancreatic serous cystadenoma. *(speedy) User:Amaitra1/Serous cystic neoplasms. *(request speedy, got stubify) ...

https://en.m.wikipedia.org/wiki/User:Dlthewave

See pancreatic tumors, benign or malignant (pancreatic cancer). Serous cystadenoma of the pancreas Solid pseudopapillary ...

https://en.wikipedia.org/wiki/Pancreatic_disease

... known as chocolate cysts Hemorrhagic ovarian cyst Dermoid cyst Ovarian serous cystadenoma Ovarian mucinous cystadenoma ...

https://en.wikipedia.org/wiki/Ovarian_cyst

Cystadenoma (mucinous/serous) Cystadenocarcinoma Islet cell tumors (neuroendocrine tumors) Papillary cystic neoplasms Lymphoma ...

https://en.wikipedia.org/wiki/Pancreatectomy

... pancreatic serous cystadenoma), endolymphatic sac tumor, and bilateral papillary cystadenomas of the epididymis (men) or broad ...

https://en.wikipedia.org/wiki/Von_Hippel–Lindau_disease

... carcinoma Papillary renal cell carcinoma Micropapillary subtype of lung adenocarcinoma Ovarian papillary serous cystadenoma and ... Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... cystadenocarcinoma Endometrial adenocarcinomas (Papillary serous carcinoma ~3%-4%) Meningiomas, in the central nervous system ...

https://en.wikipedia.org/wiki/Psammoma_body

Pancreatic serous cystadenoma Pancreatic serous cystadenocarcinoma Pancreatic mucinous cystic tumors (13.4%) Pancreatic ... Pancreatic intraductal papillary mucinous tumors (most common diagnosis - 52.6%) Pancreatic serous cystic tumors (20.6%) ... mucinous cystadenoma Pancreatic mucinous cystadenocarcinoma Parra-Herran, C. E.; Garcia, M. T.; Herrera, L; Bejarano, P. A. ( ...

https://en.wikipedia.org/wiki/Cystic_lesions_of_the_pancreas

Primary splenic artery aneurysm ruptured into pancreatic serous cystadenoma. Turk J Gastroenterol 19:57-63 (2008) 40. Mungan Z ...

https://en.wikipedia.org/wiki/Zeynel_Mungan

ISBN 1-4160-2999-0. Picture of serous cystadenoma Serous cystadenoma of pancreas at eMedicine Biliary cystadenoma/ ... serous cystadenoma (8441-8442) papillary cystadenoma (8450-8451, 8561) mucinous cystadenoma (8470-8473) Bile duct cystadenoma ( ... 8161) Endometrioid cystadenoma (8380) Appendiceal mucinous cystadenoma The term "cystadenoma" may also refer to a hidrocystoma ... Cystadenoma (or "cystoma") is a type of cystic adenoma. When malignant, it is called cystadenocarcinoma. When not otherwise ...

https://en.wikipedia.org/wiki/Cystadenoma

... majority of microcystic pancreatic masses representing alternate disease processes such as the more benign serous cystadenoma. ... Serous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. Most commonly the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-7. doi:10.1097/01 ... 13(10):1864-8 (2009 month=October). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Check ...

https://en.wikipedia.org/wiki/Serous_cystadenocarcinoma

Sixty percent are benign (cystadenoma), 10% are borderline and 30% are malignant (cystadenocarcinoma). Benign serous tumours ... Malignant serous tumours are solid, may be cystic and often show haemorrhage and necrosis. They are lined by a complex ... Serous tumours are part of the surface epithelial-stromal tumour group of ovarian neoplasms, which derive from Mullerian ... Serous carcinomas often have bulky peritoneal and omental metastases, and spread to the lymph nodes is frequent. Unsurprisingly ...

https://en.wikipedia.org/wiki/Serous_tumour

Serous tumour Cytopathology Ovarian serous cystadenoma Mesothelioma Serous Membranes & Cavities Lecture. Veterinary Anatomy Web ... Uterine serous carcinoma, also known as uterine papillary serous carcinoma, a type of uterine cancer. Fallopian tube serous ... Cervical serous carcinoma, a rare type of cervical cancer. Primary peritoneal serous carcinoma, a very rare cancer that arise ... a serous cavity). Serous lined cavities include the peritoneum, pericardium and pleural space and tunica vaginalis. Cytologic ...

https://en.wikipedia.org/wiki/Serous_carcinoma

... may refer to: Ovarian serous cystadenoma, a very common benign tumour of the ovary. Pancreatic serous ... cystadenoma, also known as serous microcystic adenoma.. ...

https://en.wikipedia.org/wiki/Serous_cystadenoma

Papillary serous cystadenoma Papillary serous cystadenocarcinoma of the ovary images: [1] Kosary, Carol L. (2007). "Chapter 16 ... Papillary serous cystadenocarcinomas are the most common form of malignant ovarian cancer making up 26 percent of ovarian ... Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenocarcinomas may exhibit psammoma bodies upon histopathology. ...

https://en.wikipedia.org/wiki/Papillary_serous_cystadenocarcinoma

... , also known as serous cystadenoma of the pancreas and serous microcystic adenoma, a benign tumour ... Ovarian serous cystadenoma Pancreatic mucinous cystadenoma Solid pseudopapillary neoplasm Colonna, J.; Plaza, JA.; Frankel, WL ... Those that are benign, that have not spread to other organs, are designated "serous cystadenoma". Serous cystadenomas can be ... 2008). "Serous cystadenoma of the pancreas: clinical and pathological features in 33 patients". Pancreatology. 8 (2): 135-41. ...

https://en.wikipedia.org/wiki/Pancreatic_serous_cystadenoma

... , also (less precisely) known as serous cystadenoma, is the most common ovarian neoplasm, ... also called serous borderline tumours, that may transform into serous carcinoma. Serous cystadenomas (of the ovary) are not ... Ovarian cancer Pancreatic serous cystadenoma Serous carcinoma Human Reproduction. University of Utah Medpath http://library.med ... serous carcinoma), and (2) does not share genetic traits of indeterminate serous tumours, ...

https://en.wikipedia.org/wiki/Ovarian_serous_cystadenoma

It includes serous tumour, endometrioid tumor, and mucinous tumour. They can be benign (cystadenoma) or malignant ( ...

https://en.wikipedia.org/wiki/Ovarian_tumor

... is a group of tumors. An example is cystadenoma. Cyst Mucinous, Mucous gland Serous, ...

https://en.wikipedia.org/wiki/Cystic,_mucinous,_and_serous_neoplasms

... types Serous tumor of borderline malignancy Serous carcinoma Well differentiated endometrioid tumor Mucinous cystadenoma ... structures Adenomatoid tumor Malignant and Benign Mesothelioma Adenocarcinoma of the epididymis Papillary cystadenoma of the ...

https://en.wikipedia.org/wiki/Testicular_cancer

... cystadenoma (serous or mucinous), diverticular or appendiceal abscess, nerve sheath tumor, pelvic kidney, ureteral or bladder ... Serous carcinomas are thought to begin in the Fallopian tube. Histologically, serous adenocarcinomas have psammoma bodies. Low- ... Serous carcinomas may develop from serous tubal intraepithelial carcinoma, rather than developing spontaneously from ovarian ... Low-grade serous carcinoma is less aggressive than high-grade serous carcinomas, though it does not typically respond well to ...

https://en.wikipedia.org/wiki/Ovarian_cancer

... serous MeSH C04.557.470.590.485 --- cystadenoma MeSH C04.557.470.590.485.225 --- cystadenoma, mucinous MeSH C04.557.470.590. ... cystadenoma, papillary MeSH C04.557.470.035.320.240 --- cystadenoma, serous MeSH C04.557.470.035.415 --- growth hormone- ... 485.230 --- cystadenoma, papillary MeSH C04.557.470.590.485.240 --- cystadenoma, serous MeSH C04.557.470.590.580 --- ... cystadenoma MeSH C04.557.470.035.320.225 --- cystadenoma, mucinous MeSH C04.557.470.035.320.230 --- ...

https://en.wikipedia.org/wiki/List_of_MeSH_codes_(C04)

Mucinous cystadenoma of the pancreas Mucinous cystadenoma Pancreatic cysts Pancreatic serous cystadenoma Parra-Herran, C. E.; ... Mucinous cystadenoma of the pancreas Mucinous cystadenoma of the pancreas Mucinous cystadenoma of the pancreas ... Pancreatic mucinous cystadenoma, also known as "mucinous cystadenoma of the pancreas", is a benign tumour of pancreas. It is ...

https://en.wikipedia.org/wiki/Pancreatic_mucinous_cystadenoma

Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...

https://en.wikipedia.org/wiki/Adenomyoma

Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...

https://en.wikipedia.org/wiki/Sarcoma_botryoides

Ovarian serous cystadenoma. *Mucinous cystadenoma. *Cystadenocarcinoma *Papillary serous cystadenocarcinoma. *Krukenberg tumor ...

https://en.wikipedia.org/wiki/Granulosa_cell_tumour

NOS M8441/0 Serous cystadenoma, NOS Serous cystoma Serous microcystic adenoma M8441/3 Serous cystadenocarcinoma, NOS (C56.9) ... Serous adenocarcinoma, NOS Serous carcinoma, NOS M8442/1 Serous cystadenoma, borderline malignancy (C56.9) Serous tumor, NOS, ... M8460/0 Papillary serous cystadenoma, NOS (C56.9) M8460/3 Papillary serous cystadenocarcinoma (C56.9) Papillary serous ... M8462/1 Serous papillary cystic tumor of borderline malignancy (C56.9) Papillary serous cystadenoma, borderline malignancy ...

https://en.wikipedia.org/wiki/International_Classification_of_Diseases_for_Oncology